Verenium and BP Extend Galaxy Joint Development Program
Funding extended while companies continue to negotiate long-term partnership
CAMBRIDGE, Mass., March 1, 2010 /PRNewswire via COMTEX News Network/ -- Verenium Corporation (Nasdaq: VRNM), a
pioneer in the development of next-generation cellulosic ethanol and high-performance specialty enzymes, today announced
that it has extended the joint development program established in August 2008 with partner BP for an additional month until April
1, 2010. BP and Verenium will continue their ongoing joint development work to accelerate the development and
commercialization of cellulosic ethanol, while the two parties continue negotiations for a longer-term collaboration.
Verenium will
receive an additional $2.5 million from BP to co-fund the cellulosic ethanol program for the month of March."Both Verenium and BP remain committed to advancing our cellulosic ethanol technology and agreeing on an appropriate
structure for doing so," said Carlos A. Riva, President and Chief Executive Officer at Verenium.
The material terms of this extension agreement are described in more detail in the Company's Current Report on Form 8-K filed
on March 1, 2010 with the Securities and Exchange Commission.
About Verenium
Verenium Corporation is a leader in the development and commercialization of cellulosic ethanol, an environmentally-friendly
and renewable transportation fuel, as well as high-performance specialty enzymes for applications within the biofuels, industrial,
and animal health markets. The Company possesses integrated, end-to-end capabilities and cutting-edge technology in pretreatment,
novel enzyme development, fermentation and project development for next-generation biofuels. Through Vercipia, a
50-50 joint venture with BP, the Company is moving rapidly to commercialize cellulosic technology for the production of ethanol
from a wide array of non-food feedstocks, including dedicated energy crops, agricultural waste, and wood products.
In addition
to the vast potential for biofuels, a multitude of large-scale industrial opportunities exist for the Company for products derived
from the production of low-cost, biomass-derived sugars.
Verenium's Specialty Enzyme business harnesses the power of enzymes to create a broad range of specialty products to meet
high-value commercial needs. Verenium's world class R&D organization is renowned for its capabilities in the rapid screening,
identification, and expression of enzymes-proteins that act as the catalysts of biochemical reactions.
For more information on
Verenium, visit http://www.verenium.com.
Forward Looking Statements
Statements in this press release that are not strictly historical are "forward-looking" and involve a high degree of risk and
uncertainty. These include, but are not limited to, statements related to the Company's operations, capabilities,
commercialization activities, joint ventures, target markets, cellulosic ethanol facilities, and future financial performance, results
and objectives, all of which are prospective. Such statements are only predictions, and actual events or results may differ
materially from those projected in such forward-looking statements. Factors that could cause or contribute to the differences
include, but are not limited to, risks associated with Verenium's technologies, risks associated with the costs, labor requirements
and labor availability associated with Verenium's demonstration plant, risks associated with Verenium's ability to obtain
additional capital to support its planned operations and financial obligations, risks associated with Verenium's dependence on
patents and proprietary rights, risks associated with Verenium's protection and enforcement of its patents and proprietary rights,
technological, regulatory, competitive and other risks related to development, production, and commercialization of cellulosic
ethanol and other biofuels and related technologies and the commercial prospects of those industries, Verenium's dependence
on existing collaboration, joint venture, manufacturing, and/or license agreements, and its ability to achieve milestones under
existing and future collaboration agreements, the ability of Verenium and its partners to commercialize its technologies and
products (including by obtaining any required regulatory approvals) using Verenium's technologies and timing for launching any
commercial products and projects, the ability of Verenium and its collaborators to market and sell any products that it or they
commercialize, the development or availability of competitive products or technologies, the future ability of Verenium to enter into
and/or maintain collaboration and joint venture agreements and licenses, changes in the U.S. or global energy markets and
laws and regulations applicable to them, and risks and other uncertainties more fully described in the Company's filings with the
Securities and Exchange Commission, including, but not limited to, the Company's annual report on Form 10-K for the year
ended December 31, 2008, the Company's quarterly report on Form 10-Q for the three months ended September 30, 2009 and
any updates contained in its subsequently filed quarterly or annual reports on Forms 10-Q and 10-K. These forward-looking
statements speak only as of the date hereof, and the Company expressly disclaims any intent or obligation to update these
forward-looking statements.
Contacts:
Kelly Lindenboom Sarah Carmody
Vice President, Corporate
Communications Manager, Corporate Communications
617-674-5335 617-674-5357
kelly.lindenboom@verenium.com sarah.carmody@verenium.com
SOURCE Verenium Corporation
Copyright (C) 2010 PR Newswire. All rights reserved
